CEREBROPROTEIN HYDROLYSATE 60mg
Cerebroprotein Hydrolysate is a mixture of low-molecular-weight peptides derived from porcine brain proteins. It has gained attention in neurodegenerative and cognitive disorder research for its potential neuroprotective, neurotrophic, and cognitive-enhancing properties. This peptide complex is believed to support neuronal repair, promote synaptic plasticity, and reduce oxidative stress, making it a candidate in stroke recovery, dementia, and traumatic brain injury protocols.
All peptides offered by 1stPharma are produced through the lyophilization (freeze-drying) process, a method that preserves molecular stability during handling and transport for approximately 3–4 months. Once reconstituted with bacteriostatic water, the solution must be stored under refrigeration to maintain integrity, where it generally remains viable for up to 30 days. Lyophilization, also referred to as cryodesiccation, is a specialized dehydration technique in which the compound is frozen and then placed under reduced pressure. This causes the frozen water content to sublimate directly from solid ice to vapor, leaving behind a stable, crystalline peptide powder. The resulting white, porous material can be kept at room temperature until reconstitution is required. After delivery, peptides should be safeguarded from light exposure and stored in a cool environment. For short-term use spanning several days to weeks, refrigeration at or below 4°C (39°F) is recommended. While lyophilized peptides may remain structurally intact at room temperature for weeks, cold storage provides added assurance of stability for ongoing research. For extended preservation lasting months or years, ultra-low freezing is preferred. Storage at –80°C (–112°F) offers the most reliable option for maintaining peptide quality and consistency over long durations. For detailed guidance on peptide handling and storage protocols, please refer to: Peptide Storage Information – 1stPharma.com For extended preservation, particularly for storage spanning multiple months to years, peptides are best kept in ultra-low freezers at approximately –80°C (–112°F). Under these long-term conditions, structural stability is maximized, ensuring peptides retain their quality and suitability for future research applications.
Overview
Cerebroprotein hydrolysate is typically administered intramuscularly or intravenously in clinical settings, particularly in Europe and parts of Asia. Its mechanism of action is hypothesized to involve the activation of brain-derived neurotrophic factors (BDNF), stimulation of neurogenesis, and enhancement of mitochondrial activity. Additionally, studies suggest that it may suppress neuronal apoptosis and inflammatory cytokines following brain injury.
Chemical Composition
Cerebroprotein Hydrolysate is not a single peptide but a mixture of biologically active peptides with molecular weights generally under 10 kDa. It is derived through enzymatic hydrolysis of porcine brain proteins, resulting in a bioavailable formulation that can cross the blood-brain barrier. Its exact composition varies by manufacturer and batch, making it unique among peptide-based nootropic therapies.
Research and Clinical Studies
- Stroke Recovery: Clinical trials have investigated its use in ischemic stroke rehabilitation.
Patients administered cerebroprotein hydrolysate exhibited improved NIH Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores, indicating enhanced motor and cognitive recovery. • Alzheimer’s Disease: Studies in Alzheimer’s patients showed potential benefits in cognition and memory, especially when combined with standard anti-dementia medications. • Traumatic Brain Injury: Animal models and clinical observations suggest neuroprotective actions through reduction of neuronal cell death and promotion of synaptic recovery. • Mitochondrial Protection: Evidence suggests that it enhances ATP production and reduces oxidative damage, contributing to energy regulation in neuronal tissues.
Mechanisms of Action
Cerebroprotein Hydrolysate’s proposed mechanisms include: – Upregulation of BDNF and
NGF (nerve growth factor) – Inhibition of pro-inflammatory cytokines (e.g., TNF-α, IL-6) Reduction of excitotoxicity and glutamate overload – Mitochondrial membrane stabilization and ROS scavenging – Enhanced neuronal plasticity and synaptogenesis
Safety and Considerations
Cerebroprotein hydrolysate has been generally well-tolerated in clinical trials, with occasional mild adverse effects such as headaches or injection site reactions. It is not approved by the FDA in the United States, but it is available in various countries under brand names like Cerebrolysin®. Due to its porcine origin, it should be used cautiously in individuals with allergies or dietary restrictions regarding animal-derived compounds.
Disclaimer
All products offered by 1stPharma.com are intended strictly for laboratory and scientific research purposes only. These products are not approved by the FDA, are not medicines or supplements, and are not sold for human consumption, medical treatment, or veterinary use. Any discussion of potential benefits is based solely on preclinical findings.
| Packing |
60mg |
|---|
Reviews
There are no reviews yet.